Skip to main content
Have a personal or library account? Click to login
Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience Cover

Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience

Radiology and Oncology
Volume 44 (2010): Issue 2 (June 2010)
By: ,  ,  ,  ,  ,  ,   and    
Open Access
|May 2010
References

References

  1. Velnar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours.2010; 44: 13-18.
    Open DOISearch in Google Scholar
  2. Kachanov DY, 2, Dobrenkov KV, Shamanskaya TV, 2, Abdullaev RT, 2, Inushkina EV, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation.2008; 42: 39-44.
    Open DOISearch in Google Scholar
  3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial.2009; 10: 459-66.
    Open DOISearch in Google Scholar
  4. Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme.2007; 82: 133-9.
    Open DOISearch in Google Scholar
  5. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.2002; 8: 180-7.
    Search in Google Scholar
  6. Steinbach JP, Blaicher HP, Herrlinger U, Wick W, Nägele T, Meyermann R, et al. Surviving glioblastoma for more than 5 years: The patient's perspective.2006; 66: 239-42.
    Open DOISearch in Google Scholar
  7. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma.2002; 62: 6205-10.
    Search in Google Scholar
  8. McLendon RE and Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?2003; 98: 1745-8.
    Open DOISearch in Google Scholar
  9. Senger D, Cairncross JG, Forsyth PAJ. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?2003; 9: 214-21.
    Open DOISearch in Google Scholar
  10. Scott JN, Rewcastle NB, Brasher PMA, Fulton D, MacKinnon JA, Hamilton M, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study.1999; 46: 183-8.
    Open DOISearch in Google Scholar
  11. Vertosick FT, Selker RG. Long-term survival after the diagnosis of malignant glioma. A series of 22 patients surviving more than 4 years after diagnosis.1992; 38: 359-63.
    Open DOISearch in Google Scholar
  12. Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM. Long-term survival in patients with supratentorial glioblastoma.1998; 36: 61-4.
    Open DOISearch in Google Scholar
  13. Morita M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR. Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.1996; 27: 259-66.
    Open DOISearch in Google Scholar
  14. Nieder C, Grosu AL, Astner S, Molls M. Treatment of unresectable glioblastoma multiforme.2005; 25: 4605-10.
    Search in Google Scholar
  15. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.2008; 9: 29-38.
    Open DOISearch in Google Scholar
  16. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.1998; 40: 51-5.
    Open DOISearch in Google Scholar
  17. Vranic A. Antigen expression on recurrent meningioma cells.2010; 44: 107-12.
    Open DOISearch in Google Scholar
  18. Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme.2007; 83: 91-3.
    Open DOISearch in Google Scholar
  19. Hau P, Stupp R, Hegi ME. MGMT methylation status: the advent of stratified therapy in glioblastoma?2007; 23: 97-104.
    Open DOISearch in Google Scholar
  20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma.2005; 352: 997-1003.
    Open DOISearch in Google Scholar
  21. Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.2009; 27: 1257-61
    Open DOISearch in Google Scholar
  22. Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis.2009; 151: 1349-58.
    Open DOISearch in Google Scholar
  23. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme.2007; 130: 2596-606.
    Open DOISearch in Google Scholar
  24. Balana C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, et al. O-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme.2003; 9: 1461-8.
    Search in Google Scholar
  25. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y. Correlation between promoter hypermethylation of the O-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy.2004; 54: 349-57.
    Open DOISearch in Google Scholar
  26. Blanc JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.2004; 68: 275-83.
    Open DOISearch in Google Scholar
  27. Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma.2006; 24: 35-40.
    Open DOISearch in Google Scholar
  28. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.2000; 343: 1350-4.
    Open DOISearch in Google Scholar
  29. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neurooncologia (GICNO).2006; 95: 1155-60.
    Open DOISearch in Google Scholar
  30. Hassler M, Seidl S, Fazeny-Doerner B, Preusser M, Hainfellner J, Rössler K, et al. Diversity of cytogenetic and pathohistologic profiles in glioblastoma.2006; 166: 46-55.
    Open DOISearch in Google Scholar
  31. Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, et al. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities.2007; 83: 173-9.
    Open DOISearch in Google Scholar
  32. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.2004; 10: 1871-4.
    Open DOISearch in Google Scholar
  33. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.2006; 24: 4412-7.
    Open DOISearch in Google Scholar
  34. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue.2007; 87: 392-7.
    Open DOISearch in Google Scholar
  35. Aldape KD, Jones G, Wang M, Hegi M, Janzer RC, Stupp R, et al. MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma [abstract].2009; 27(Suppl), 15S. No. 2051.
    Open DOISearch in Google Scholar
  36. Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.2006; 20: 1-6.
    Search in Google Scholar
  37. Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, De Campos JM, et al. Promoter hypermethylation of multiple genes in astrocytic gliomas.2003; 22: 601-8.
    Search in Google Scholar
  38. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?2010; 6: 39-51.
    Open DOISearch in Google Scholar
  39. Preusser M, Elezi L, Hainfellner JA. Poor reliability and reproducibility of PCR-based testing of O-methylguanine-DNA methyltransferase gene () promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens.2008; 27: 388-90.
    Open DOISearch in Google Scholar
  40. Ho DM, Hsu CY, Ting LT, Chiang H. MIB-1 and DNA Topoisomerase IIα could be helpful for predicting long-term survival of patients with glioblastoma.2003; 119: 715-22.
    Open DOISearch in Google Scholar
  41. Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C. Glioblastoma multiforme with long-term survival.2005; 53: 329-32.
    Open DOISearch in Google Scholar
  42. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors.2009; 95: 301-5.
    Open DOISearch in Google Scholar
  43. Gojkovic Horvat A, Kovac V, Strojan P. Radiotherapy in palliative treatment of painful bone metastases.2009; 43: 213-24.
    Search in Google Scholar
  44. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas.2005; 26: 2466-74.
    Search in Google Scholar
  45. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme.1996; 27: 65-73.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-010-0023-y | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 113 - 120
Published on: May 24, 2010
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
glioblastoma multiforme (GBM),
high grade glioma,
MGMT promoter methylation,
hypermethylation,
long-term survival
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2010 Martina Baur, Matthias Preusser, Maria Piribauer, Katarzyna Elandt, Marco Hassler, Marcus Hudec, Christian Dittrich, Christine Marosi, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 44 (2010): Issue 2 (June 2010)
Previous article
Next article